Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Streptococcus pneumoniae | 93 | 2024 | 764 | 13.370 |
Why?
|
Pneumococcal Infections | 74 | 2024 | 529 | 11.590 |
Why?
|
Influenza, Human | 71 | 2024 | 1541 | 9.240 |
Why?
|
Vaccines | 29 | 2024 | 842 | 7.820 |
Why?
|
Disease Outbreaks | 61 | 2024 | 1761 | 7.170 |
Why?
|
Pneumococcal Vaccines | 48 | 2024 | 414 | 6.530 |
Why?
|
Carrier State | 38 | 2024 | 529 | 5.340 |
Why?
|
Communicable Diseases | 22 | 2024 | 874 | 5.010 |
Why?
|
Pandemics | 56 | 2024 | 8748 | 4.230 |
Why?
|
Drug Resistance, Bacterial | 32 | 2024 | 1063 | 4.100 |
Why?
|
Anti-Bacterial Agents | 63 | 2024 | 7470 | 4.060 |
Why?
|
Influenza A Virus, H1N1 Subtype | 24 | 2024 | 452 | 3.930 |
Why?
|
Communicable Diseases, Emerging | 9 | 2023 | 149 | 3.440 |
Why?
|
Drug Resistance, Microbial | 25 | 2022 | 830 | 3.160 |
Why?
|
Pneumonia, Viral | 22 | 2020 | 3238 | 3.040 |
Why?
|
Coronavirus Infections | 21 | 2020 | 3115 | 3.020 |
Why?
|
Influenza A virus | 12 | 2018 | 460 | 2.770 |
Why?
|
Nasopharynx | 31 | 2018 | 420 | 2.740 |
Why?
|
Epidemics | 15 | 2022 | 517 | 2.590 |
Why?
|
Influenza Vaccines | 16 | 2024 | 780 | 2.520 |
Why?
|
Vaccination | 36 | 2024 | 3437 | 2.430 |
Why?
|
Neisseria gonorrhoeae | 10 | 2020 | 249 | 2.310 |
Why?
|
Disease Transmission, Infectious | 15 | 2020 | 560 | 2.230 |
Why?
|
Models, Biological | 41 | 2021 | 9493 | 2.200 |
Why?
|
Vaccines, Conjugate | 17 | 2024 | 334 | 2.100 |
Why?
|
Seasons | 19 | 2024 | 1524 | 2.080 |
Why?
|
Serotyping | 28 | 2018 | 331 | 1.960 |
Why?
|
Bacterial Infections | 18 | 2024 | 1397 | 1.950 |
Why?
|
Gonorrhea | 9 | 2020 | 355 | 1.950 |
Why?
|
Antigens, Bacterial | 13 | 2017 | 1150 | 1.940 |
Why?
|
Communicable Disease Control | 14 | 2024 | 857 | 1.880 |
Why?
|
Research Design | 16 | 2021 | 6211 | 1.850 |
Why?
|
Bacteria | 19 | 2022 | 2216 | 1.820 |
Why?
|
Viral Vaccines | 5 | 2020 | 596 | 1.800 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2024 | 10396 | 1.800 |
Why?
|
Antigenic Variation | 6 | 2019 | 117 | 1.790 |
Why?
|
Bacterial Capsules | 11 | 2015 | 247 | 1.780 |
Why?
|
Models, Statistical | 24 | 2021 | 5107 | 1.770 |
Why?
|
Models, Theoretical | 34 | 2024 | 3573 | 1.740 |
Why?
|
Coronavirus | 5 | 2020 | 156 | 1.600 |
Why?
|
Bacterial Vaccines | 9 | 2018 | 400 | 1.540 |
Why?
|
Oseltamivir | 5 | 2016 | 76 | 1.430 |
Why?
|
Immunity, Herd | 7 | 2021 | 48 | 1.410 |
Why?
|
Influenza A Virus, H5N1 Subtype | 8 | 2019 | 117 | 1.410 |
Why?
|
Drug Resistance, Multiple, Bacterial | 9 | 2019 | 591 | 1.370 |
Why?
|
Population Surveillance | 15 | 2024 | 2594 | 1.360 |
Why?
|
Antibodies, Bacterial | 16 | 2018 | 1478 | 1.360 |
Why?
|
Humans | 366 | 2024 | 767991 | 1.360 |
Why?
|
Virus Diseases | 6 | 2024 | 723 | 1.350 |
Why?
|
Immune Evasion | 6 | 2024 | 375 | 1.340 |
Why?
|
Respiratory Syncytial Virus Infections | 4 | 2019 | 365 | 1.330 |
Why?
|
Ethics, Research | 5 | 2019 | 178 | 1.300 |
Why?
|
Genome, Bacterial | 12 | 2024 | 796 | 1.290 |
Why?
|
Biomedical Research | 11 | 2024 | 3463 | 1.280 |
Why?
|
Computer Simulation | 26 | 2021 | 6283 | 1.280 |
Why?
|
Clinical Trials as Topic | 9 | 2021 | 8052 | 1.240 |
Why?
|
Cross Infection | 10 | 2024 | 1426 | 1.220 |
Why?
|
Public Health | 14 | 2024 | 2679 | 1.210 |
Why?
|
Seroepidemiologic Studies | 7 | 2021 | 404 | 1.200 |
Why?
|
Disease Susceptibility | 12 | 2024 | 1793 | 1.190 |
Why?
|
Staphylococcal Infections | 12 | 2020 | 1398 | 1.170 |
Why?
|
Containment of Biohazards | 5 | 2018 | 39 | 1.150 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 7 | 2024 | 704 | 1.090 |
Why?
|
Selection, Genetic | 15 | 2021 | 877 | 1.080 |
Why?
|
Azithromycin | 4 | 2022 | 201 | 1.080 |
Why?
|
Penicillin Resistance | 8 | 2020 | 77 | 1.060 |
Why?
|
Mass Vaccination | 5 | 2021 | 111 | 1.040 |
Why?
|
Epidemiologic Studies | 3 | 2020 | 677 | 1.040 |
Why?
|
Antiviral Agents | 12 | 2016 | 3073 | 1.000 |
Why?
|
Security Measures | 2 | 2024 | 83 | 0.970 |
Why?
|
Influenza in Birds | 4 | 2013 | 76 | 0.950 |
Why?
|
Travel | 7 | 2021 | 805 | 0.940 |
Why?
|
Sexual Partners | 5 | 2019 | 805 | 0.940 |
Why?
|
Ciprofloxacin | 3 | 2017 | 313 | 0.930 |
Why?
|
Penicillins | 7 | 2022 | 404 | 0.930 |
Why?
|
Epidemiologic Research Design | 2 | 2018 | 368 | 0.910 |
Why?
|
Ethics, Medical | 2 | 2022 | 785 | 0.910 |
Why?
|
Macrolides | 5 | 2022 | 204 | 0.900 |
Why?
|
Staphylococcus aureus | 11 | 2020 | 1430 | 0.890 |
Why?
|
Epidemiologic Methods | 7 | 2020 | 1326 | 0.890 |
Why?
|
Microbiology | 1 | 2024 | 70 | 0.870 |
Why?
|
Sepsis | 5 | 2020 | 2608 | 0.870 |
Why?
|
Transformation, Bacterial | 5 | 2014 | 79 | 0.860 |
Why?
|
Models, Immunological | 5 | 2019 | 518 | 0.860 |
Why?
|
Immunity, Cellular | 3 | 2019 | 1561 | 0.840 |
Why?
|
Host-Pathogen Interactions | 8 | 2018 | 1469 | 0.830 |
Why?
|
Haemophilus influenzae | 5 | 2016 | 177 | 0.820 |
Why?
|
Antibiosis | 4 | 2009 | 46 | 0.800 |
Why?
|
Whooping Cough | 3 | 2019 | 87 | 0.790 |
Why?
|
Pneumonia, Pneumococcal | 6 | 2011 | 133 | 0.790 |
Why?
|
Ebola Vaccines | 3 | 2018 | 25 | 0.780 |
Why?
|
Antibodies, Viral | 5 | 2021 | 3216 | 0.780 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2019 | 361 | 0.780 |
Why?
|
Schools | 5 | 2021 | 1498 | 0.770 |
Why?
|
Immunization Programs | 7 | 2021 | 267 | 0.770 |
Why?
|
Drug Resistance, Viral | 7 | 2016 | 869 | 0.760 |
Why?
|
Sentinel Surveillance | 6 | 2020 | 292 | 0.750 |
Why?
|
Prevalence | 33 | 2024 | 15867 | 0.750 |
Why?
|
Escherichia coli Infections | 5 | 2020 | 524 | 0.750 |
Why?
|
Hemorrhagic Fever, Ebola | 5 | 2018 | 424 | 0.740 |
Why?
|
Humidity | 3 | 2013 | 207 | 0.740 |
Why?
|
Drug Prescriptions | 4 | 2022 | 1667 | 0.740 |
Why?
|
Coronaviridae Infections | 1 | 2020 | 10 | 0.730 |
Why?
|
Hospitalization | 12 | 2024 | 10840 | 0.710 |
Why?
|
Adaptive Immunity | 4 | 2020 | 733 | 0.710 |
Why?
|
Orthomyxoviridae Infections | 2 | 2013 | 255 | 0.690 |
Why?
|
United States | 55 | 2024 | 73027 | 0.690 |
Why?
|
Child, Preschool | 57 | 2024 | 42665 | 0.680 |
Why?
|
Disaster Planning | 4 | 2019 | 559 | 0.680 |
Why?
|
China | 8 | 2024 | 2395 | 0.680 |
Why?
|
Severe Acute Respiratory Syndrome | 3 | 2007 | 136 | 0.670 |
Why?
|
Genetic Variation | 11 | 2019 | 6611 | 0.670 |
Why?
|
Incidence | 37 | 2024 | 21532 | 0.660 |
Why?
|
Therapeutic Human Experimentation | 1 | 2019 | 43 | 0.650 |
Why?
|
Data Interpretation, Statistical | 6 | 2020 | 2708 | 0.650 |
Why?
|
Pneumonia, Bacterial | 2 | 2013 | 320 | 0.650 |
Why?
|
Asymptomatic Infections | 2 | 2024 | 136 | 0.650 |
Why?
|
Cephalosporins | 3 | 2016 | 200 | 0.650 |
Why?
|
Off-Label Use | 1 | 2021 | 185 | 0.640 |
Why?
|
Microbial Sensitivity Tests | 18 | 2020 | 1967 | 0.640 |
Why?
|
Chemoprevention | 3 | 2019 | 327 | 0.640 |
Why?
|
Meningitis, Meningococcal | 1 | 2019 | 43 | 0.640 |
Why?
|
Hospital Bed Capacity | 1 | 2020 | 202 | 0.640 |
Why?
|
Post-Exposure Prophylaxis | 2 | 2024 | 113 | 0.640 |
Why?
|
Meningococcal Vaccines | 5 | 2019 | 96 | 0.640 |
Why?
|
Basic Reproduction Number | 5 | 2020 | 38 | 0.620 |
Why?
|
Sexual Behavior | 3 | 2019 | 2197 | 0.620 |
Why?
|
Anti-Infective Agents | 2 | 2018 | 983 | 0.610 |
Why?
|
Escherichia coli | 9 | 2022 | 4215 | 0.610 |
Why?
|
Risk Assessment | 17 | 2022 | 24314 | 0.610 |
Why?
|
Genetic Engineering | 2 | 2015 | 935 | 0.600 |
Why?
|
Infant | 47 | 2024 | 36534 | 0.600 |
Why?
|
Models, Genetic | 10 | 2017 | 3447 | 0.600 |
Why?
|
Haemophilus Infections | 3 | 2012 | 94 | 0.590 |
Why?
|
Child | 65 | 2024 | 80906 | 0.590 |
Why?
|
Science | 1 | 2020 | 236 | 0.570 |
Why?
|
Metagenomics | 4 | 2020 | 474 | 0.570 |
Why?
|
Toxins, Biological | 1 | 2017 | 59 | 0.570 |
Why?
|
Biometry | 1 | 2020 | 570 | 0.560 |
Why?
|
Orthomyxoviridae | 5 | 2014 | 148 | 0.560 |
Why?
|
Bacterial Proteins | 11 | 2018 | 3841 | 0.560 |
Why?
|
Family Characteristics | 6 | 2022 | 1003 | 0.560 |
Why?
|
Health Plan Implementation | 1 | 2020 | 338 | 0.550 |
Why?
|
Research | 4 | 2018 | 1979 | 0.540 |
Why?
|
Flavivirus | 1 | 2016 | 23 | 0.540 |
Why?
|
Yellow Fever Vaccine | 1 | 2016 | 38 | 0.540 |
Why?
|
Adolescent | 46 | 2024 | 89155 | 0.530 |
Why?
|
Population Dynamics | 9 | 2018 | 314 | 0.530 |
Why?
|
Drugs, Investigational | 1 | 2018 | 211 | 0.530 |
Why?
|
Young Adult | 37 | 2024 | 60048 | 0.530 |
Why?
|
Viruses | 4 | 2024 | 373 | 0.520 |
Why?
|
Yellow Fever | 1 | 2016 | 54 | 0.520 |
Why?
|
Biological Evolution | 10 | 2021 | 1076 | 0.520 |
Why?
|
Statistics as Topic | 4 | 2019 | 2357 | 0.520 |
Why?
|
Age Factors | 14 | 2021 | 18407 | 0.510 |
Why?
|
Recombination, Genetic | 5 | 2018 | 1525 | 0.510 |
Why?
|
Ferrets | 2 | 2013 | 181 | 0.510 |
Why?
|
Infection Control | 6 | 2020 | 985 | 0.510 |
Why?
|
Chikungunya virus | 1 | 2016 | 56 | 0.510 |
Why?
|
Health Care Rationing | 2 | 2012 | 435 | 0.500 |
Why?
|
Zoonoses | 1 | 2016 | 180 | 0.500 |
Why?
|
Evolution, Molecular | 7 | 2024 | 1896 | 0.500 |
Why?
|
Virulence | 8 | 2018 | 1297 | 0.490 |
Why?
|
Penicillin-Binding Proteins | 3 | 2014 | 152 | 0.490 |
Why?
|
Respiration Disorders | 1 | 2018 | 364 | 0.490 |
Why?
|
Cities | 4 | 2021 | 543 | 0.480 |
Why?
|
Genetics, Population | 5 | 2018 | 943 | 0.470 |
Why?
|
Awareness | 1 | 2019 | 653 | 0.460 |
Why?
|
Fluoroquinolones | 1 | 2016 | 309 | 0.460 |
Why?
|
Immunity, Humoral | 1 | 2019 | 610 | 0.460 |
Why?
|
Meningococcal Infections | 1 | 2014 | 78 | 0.460 |
Why?
|
Cefixime | 1 | 2014 | 13 | 0.460 |
Why?
|
Influenza A Virus, H3N2 Subtype | 3 | 2024 | 85 | 0.460 |
Why?
|
Cephalosporin Resistance | 1 | 2014 | 17 | 0.460 |
Why?
|
Databases, Protein | 1 | 2016 | 390 | 0.460 |
Why?
|
Polymorphism, Genetic | 3 | 2021 | 4248 | 0.450 |
Why?
|
Interprofessional Relations | 1 | 2020 | 997 | 0.450 |
Why?
|
Bronchopneumonia | 1 | 2013 | 11 | 0.450 |
Why?
|
Immunization | 4 | 2017 | 1218 | 0.440 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2020 | 4415 | 0.440 |
Why?
|
Health Status Disparities | 3 | 2021 | 1885 | 0.440 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 1406 | 0.440 |
Why?
|
Genomics | 7 | 2020 | 5925 | 0.440 |
Why?
|
Israel | 11 | 2022 | 726 | 0.430 |
Why?
|
Sexually Transmitted Diseases | 1 | 2019 | 668 | 0.430 |
Why?
|
Parasitic Diseases | 4 | 1999 | 76 | 0.430 |
Why?
|
Static Electricity | 1 | 2013 | 260 | 0.420 |
Why?
|
Safety | 2 | 2021 | 1159 | 0.420 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1395 | 0.410 |
Why?
|
Adult | 58 | 2024 | 223583 | 0.410 |
Why?
|
Disasters | 1 | 2019 | 521 | 0.410 |
Why?
|
Outpatients | 2 | 2020 | 1600 | 0.410 |
Why?
|
Immunization, Secondary | 5 | 2022 | 373 | 0.400 |
Why?
|
El Nino-Southern Oscillation | 1 | 2012 | 2 | 0.400 |
Why?
|
Bacterial Typing Techniques | 3 | 2011 | 263 | 0.380 |
Why?
|
Computational Biology | 5 | 2020 | 3568 | 0.380 |
Why?
|
Ecology | 2 | 2019 | 105 | 0.380 |
Why?
|
Animals | 54 | 2021 | 169222 | 0.380 |
Why?
|
HIV Infections | 11 | 2022 | 17569 | 0.370 |
Why?
|
Bacterial Load | 4 | 2015 | 155 | 0.370 |
Why?
|
Virology | 2 | 2021 | 76 | 0.370 |
Why?
|
Antigens, Viral | 3 | 2013 | 995 | 0.370 |
Why?
|
Forecasting | 6 | 2022 | 2945 | 0.360 |
Why?
|
Streptococcal Infections | 1 | 2015 | 618 | 0.360 |
Why?
|
Respiratory Tract Infections | 3 | 2024 | 1014 | 0.360 |
Why?
|
Antibody Formation | 4 | 2018 | 1392 | 0.360 |
Why?
|
Publishing | 1 | 2018 | 837 | 0.360 |
Why?
|
Birds | 5 | 2019 | 166 | 0.360 |
Why?
|
Decision Making, Organizational | 1 | 2011 | 136 | 0.360 |
Why?
|
Contact Tracing | 3 | 2021 | 275 | 0.350 |
Why?
|
Phylogeny | 9 | 2022 | 2843 | 0.330 |
Why?
|
Cholera | 2 | 2015 | 754 | 0.330 |
Why?
|
Child Day Care Centers | 4 | 2009 | 122 | 0.330 |
Why?
|
Time Factors | 24 | 2021 | 40214 | 0.330 |
Why?
|
Biological Science Disciplines | 2 | 2022 | 58 | 0.320 |
Why?
|
Cluster Analysis | 7 | 2020 | 2731 | 0.320 |
Why?
|
Viral Load | 5 | 2021 | 3396 | 0.320 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3701 | 0.320 |
Why?
|
Otitis Media | 3 | 2018 | 288 | 0.320 |
Why?
|
Genotype | 10 | 2021 | 13042 | 0.320 |
Why?
|
Molecular Biology | 1 | 2012 | 573 | 0.310 |
Why?
|
Veterans | 2 | 2024 | 2669 | 0.310 |
Why?
|
Mathematics | 8 | 2004 | 704 | 0.310 |
Why?
|
Age Distribution | 6 | 2020 | 2871 | 0.310 |
Why?
|
Female | 72 | 2024 | 397113 | 0.310 |
Why?
|
Alleles | 2 | 2014 | 6894 | 0.310 |
Why?
|
Observation | 1 | 2010 | 310 | 0.300 |
Why?
|
Ambulatory Care | 1 | 2019 | 2781 | 0.300 |
Why?
|
Civil Defense | 1 | 2010 | 115 | 0.300 |
Why?
|
Pregnancy Complications, Infectious | 4 | 2021 | 2185 | 0.300 |
Why?
|
Genetic Fitness | 3 | 2015 | 120 | 0.300 |
Why?
|
Pertussis Vaccine | 2 | 2019 | 39 | 0.300 |
Why?
|
Drug Resistance, Multiple | 4 | 1998 | 255 | 0.290 |
Why?
|
Molecular Epidemiology | 5 | 2017 | 473 | 0.290 |
Why?
|
California | 6 | 2022 | 1438 | 0.290 |
Why?
|
Bayes Theorem | 9 | 2021 | 2358 | 0.290 |
Why?
|
Public Health Practice | 3 | 2020 | 221 | 0.280 |
Why?
|
Probability | 6 | 2016 | 2479 | 0.280 |
Why?
|
Behavior | 1 | 2010 | 541 | 0.280 |
Why?
|
Male | 61 | 2024 | 364641 | 0.280 |
Why?
|
Critical Illness | 1 | 2020 | 2756 | 0.280 |
Why?
|
beta-Lactamases | 3 | 2019 | 307 | 0.280 |
Why?
|
Sequence Analysis, DNA | 4 | 2020 | 4785 | 0.280 |
Why?
|
Quantitative Trait Loci | 2 | 2018 | 2131 | 0.280 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2012 | 539 | 0.280 |
Why?
|
Decision Support Techniques | 2 | 2018 | 2008 | 0.270 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2019 | 163 | 0.270 |
Why?
|
Placebos | 3 | 2021 | 1667 | 0.270 |
Why?
|
Middle Aged | 40 | 2024 | 223422 | 0.270 |
Why?
|
Weather | 2 | 2004 | 234 | 0.270 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12536 | 0.270 |
Why?
|
Singapore | 3 | 2020 | 300 | 0.270 |
Why?
|
Complement System Proteins | 1 | 2009 | 738 | 0.270 |
Why?
|
Reproduction, Asexual | 1 | 2006 | 13 | 0.270 |
Why?
|
Microbial Viability | 1 | 2007 | 237 | 0.270 |
Why?
|
Neutrophils | 5 | 2013 | 3786 | 0.260 |
Why?
|
Tuberculosis | 5 | 2018 | 2029 | 0.260 |
Why?
|
New York City | 4 | 2024 | 737 | 0.260 |
Why?
|
Hydrogen Peroxide | 2 | 2007 | 740 | 0.260 |
Why?
|
Th17 Cells | 1 | 2012 | 791 | 0.260 |
Why?
|
Aged | 37 | 2024 | 171446 | 0.260 |
Why?
|
Health Policy | 7 | 2020 | 2698 | 0.260 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2015 | 3669 | 0.260 |
Why?
|
Species Specificity | 4 | 2018 | 2415 | 0.260 |
Why?
|
Indians, North American | 4 | 2011 | 354 | 0.260 |
Why?
|
Herpesvirus 1, Human | 2 | 2002 | 743 | 0.250 |
Why?
|
Virus Shedding | 2 | 2020 | 110 | 0.250 |
Why?
|
Epistasis, Genetic | 3 | 2018 | 353 | 0.250 |
Why?
|
Markov Chains | 2 | 2012 | 979 | 0.250 |
Why?
|
Reference Books, Medical | 1 | 2005 | 22 | 0.250 |
Why?
|
AIDS Vaccines | 1 | 2012 | 900 | 0.250 |
Why?
|
Polysaccharides, Bacterial | 2 | 2006 | 582 | 0.250 |
Why?
|
Community-Acquired Infections | 4 | 2011 | 472 | 0.250 |
Why?
|
Drug Utilization | 5 | 2019 | 1190 | 0.250 |
Why?
|
Complement Factor H | 2 | 2018 | 110 | 0.250 |
Why?
|
Communication | 1 | 2019 | 3904 | 0.250 |
Why?
|
Peptidyl Transferases | 1 | 2005 | 55 | 0.240 |
Why?
|
Genes, Bacterial | 4 | 2016 | 1076 | 0.240 |
Why?
|
Streptococcal Vaccines | 1 | 2005 | 46 | 0.240 |
Why?
|
Parasites | 3 | 1999 | 160 | 0.240 |
Why?
|
Influenza B virus | 3 | 2024 | 53 | 0.240 |
Why?
|
Viral Interference | 1 | 2024 | 11 | 0.240 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2016 | 10757 | 0.240 |
Why?
|
Colony Count, Microbial | 5 | 2012 | 328 | 0.230 |
Why?
|
Measles | 3 | 2012 | 180 | 0.230 |
Why?
|
Quarantine | 3 | 2020 | 186 | 0.230 |
Why?
|
Population Density | 2 | 2023 | 193 | 0.230 |
Why?
|
South Africa | 5 | 2019 | 1873 | 0.230 |
Why?
|
Risk | 7 | 2022 | 9609 | 0.230 |
Why?
|
New York | 2 | 2021 | 882 | 0.230 |
Why?
|
Nose | 3 | 2020 | 522 | 0.220 |
Why?
|
Urban Population | 2 | 2024 | 2045 | 0.220 |
Why?
|
Databases, Factual | 2 | 2021 | 8082 | 0.210 |
Why?
|
Internet | 3 | 2018 | 3110 | 0.210 |
Why?
|
Health Surveys | 3 | 2014 | 4056 | 0.210 |
Why?
|
Kenya | 5 | 2012 | 757 | 0.210 |
Why?
|
Niger | 2 | 2020 | 38 | 0.210 |
Why?
|
Massachusetts | 12 | 2024 | 8888 | 0.210 |
Why?
|
Animal Husbandry | 1 | 2003 | 64 | 0.210 |
Why?
|
beta-Lactam Resistance | 3 | 2016 | 79 | 0.200 |
Why?
|
Selection Bias | 1 | 2024 | 360 | 0.200 |
Why?
|
Cost of Illness | 3 | 2021 | 1951 | 0.200 |
Why?
|
Genome, Human | 1 | 2015 | 4443 | 0.200 |
Why?
|
Risk Management | 2 | 2016 | 558 | 0.200 |
Why?
|
Microbial Interactions | 2 | 2012 | 74 | 0.200 |
Why?
|
Fimbriae Proteins | 2 | 2014 | 133 | 0.200 |
Why?
|
World Health Organization | 4 | 2021 | 1328 | 0.200 |
Why?
|
Immunoglobulin G | 6 | 2018 | 4564 | 0.190 |
Why?
|
Cause of Death | 1 | 2012 | 3720 | 0.190 |
Why?
|
Nipah Virus | 1 | 2021 | 12 | 0.190 |
Why?
|
Mutagenesis | 1 | 2006 | 1228 | 0.190 |
Why?
|
Administrative Personnel | 1 | 2023 | 185 | 0.190 |
Why?
|
Erythromycin | 3 | 2014 | 115 | 0.190 |
Why?
|
Homosexuality, Male | 3 | 2019 | 1344 | 0.190 |
Why?
|
Aged, 80 and over | 14 | 2021 | 59598 | 0.190 |
Why?
|
Mammals | 2 | 2020 | 1136 | 0.180 |
Why?
|
Coronaviridae | 1 | 2020 | 13 | 0.180 |
Why?
|
Haemophilus Vaccines | 2 | 1999 | 71 | 0.180 |
Why?
|
Mice | 20 | 2019 | 82024 | 0.180 |
Why?
|
Pharyngitis | 1 | 2022 | 221 | 0.180 |
Why?
|
Herpes Labialis | 1 | 2000 | 28 | 0.180 |
Why?
|
Hong Kong | 3 | 2007 | 170 | 0.180 |
Why?
|
Agriculture | 1 | 2002 | 186 | 0.180 |
Why?
|
Causality | 2 | 2022 | 1254 | 0.180 |
Why?
|
Specimen Handling | 2 | 2020 | 708 | 0.180 |
Why?
|
Asthma | 1 | 2019 | 6273 | 0.180 |
Why?
|
Coronavirus OC43, Human | 1 | 2020 | 20 | 0.180 |
Why?
|
Stochastic Processes | 4 | 2014 | 360 | 0.180 |
Why?
|
Wisconsin | 2 | 2010 | 122 | 0.170 |
Why?
|
Risk Factors | 19 | 2021 | 74936 | 0.170 |
Why?
|
Multilocus Sequence Typing | 4 | 2015 | 102 | 0.170 |
Why?
|
Phagocytosis | 2 | 2018 | 1530 | 0.170 |
Why?
|
Students | 1 | 2010 | 1744 | 0.170 |
Why?
|
Uncertainty | 2 | 2017 | 769 | 0.170 |
Why?
|
Inappropriate Prescribing | 2 | 2022 | 212 | 0.170 |
Why?
|
Vancomycin Resistance | 2 | 2014 | 125 | 0.170 |
Why?
|
Women, Working | 1 | 2020 | 86 | 0.170 |
Why?
|
History, 20th Century | 4 | 2009 | 2766 | 0.170 |
Why?
|
Social Welfare | 1 | 2020 | 87 | 0.160 |
Why?
|
Malaria, Falciparum | 2 | 2004 | 1077 | 0.160 |
Why?
|
Ducks | 1 | 2019 | 11 | 0.160 |
Why?
|
Neisseria meningitidis, Serogroup C | 1 | 2019 | 11 | 0.160 |
Why?
|
Directed Molecular Evolution | 1 | 2020 | 167 | 0.160 |
Why?
|
Nasal Mucosa | 2 | 2015 | 416 | 0.160 |
Why?
|
Infant, Newborn | 15 | 2020 | 26420 | 0.160 |
Why?
|
Death Certificates | 1 | 2020 | 172 | 0.160 |
Why?
|
Mycobacterium tuberculosis | 3 | 2013 | 1930 | 0.160 |
Why?
|
Rhinovirus | 1 | 2020 | 209 | 0.160 |
Why?
|
Mice, Inbred BALB C | 4 | 2013 | 6231 | 0.160 |
Why?
|
Immunity, Innate | 4 | 2012 | 3079 | 0.160 |
Why?
|
Hospitals | 4 | 2022 | 3886 | 0.160 |
Why?
|
Herpes Simplex | 1 | 2002 | 470 | 0.160 |
Why?
|
Mutation | 13 | 2019 | 30211 | 0.160 |
Why?
|
Morals | 1 | 2021 | 288 | 0.160 |
Why?
|
Drug Utilization Review | 1 | 2020 | 248 | 0.160 |
Why?
|
Sample Size | 2 | 2019 | 846 | 0.160 |
Why?
|
Health Services Administration | 1 | 2019 | 63 | 0.150 |
Why?
|
Cross Reactions | 1 | 2020 | 828 | 0.150 |
Why?
|
Epitopes | 2 | 2017 | 2526 | 0.150 |
Why?
|
Biohazard Release | 2 | 2021 | 8 | 0.150 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 746 | 0.150 |
Why?
|
Europe | 6 | 2023 | 3437 | 0.150 |
Why?
|
Vaccines, Inactivated | 1 | 2018 | 186 | 0.150 |
Why?
|
Mice, Inbred C57BL | 12 | 2009 | 22381 | 0.150 |
Why?
|
Blood Bactericidal Activity | 1 | 2018 | 124 | 0.150 |
Why?
|
Drug Resistance | 2 | 2006 | 1598 | 0.150 |
Why?
|
Adhesins, Bacterial | 2 | 2017 | 118 | 0.150 |
Why?
|
Host-Parasite Interactions | 2 | 1997 | 303 | 0.150 |
Why?
|
Health Priorities | 1 | 2021 | 380 | 0.150 |
Why?
|
Germany | 1 | 2020 | 883 | 0.150 |
Why?
|
Severity of Illness Index | 6 | 2024 | 15944 | 0.140 |
Why?
|
Fimbriae, Bacterial | 2 | 2009 | 138 | 0.140 |
Why?
|
Immunity | 4 | 2021 | 1003 | 0.140 |
Why?
|
Mexico | 2 | 2010 | 769 | 0.140 |
Why?
|
Vitamin D | 1 | 2011 | 3311 | 0.140 |
Why?
|
HLA Antigens | 1 | 2003 | 1334 | 0.140 |
Why?
|
Pyruvate Oxidase | 2 | 2007 | 9 | 0.140 |
Why?
|
Respiratory System | 2 | 2015 | 564 | 0.140 |
Why?
|
Linear Models | 3 | 2020 | 5884 | 0.140 |
Why?
|
Angola | 1 | 2016 | 18 | 0.140 |
Why?
|
Insect Vectors | 2 | 2016 | 136 | 0.140 |
Why?
|
Beneficence | 1 | 2017 | 56 | 0.140 |
Why?
|
Heterosexuality | 3 | 2016 | 309 | 0.140 |
Why?
|
Adaptation, Biological | 1 | 2018 | 147 | 0.140 |
Why?
|
England | 3 | 2018 | 533 | 0.140 |
Why?
|
Data Collection | 3 | 2011 | 3326 | 0.140 |
Why?
|
Survival Analysis | 4 | 2019 | 10098 | 0.140 |
Why?
|
Democratic Republic of the Congo | 1 | 2016 | 87 | 0.140 |
Why?
|
Encephalitis Virus, Japanese | 1 | 2016 | 12 | 0.140 |
Why?
|
Yellow fever virus | 1 | 2016 | 23 | 0.140 |
Why?
|
Microcephaly | 1 | 2020 | 426 | 0.130 |
Why?
|
Reproducibility of Results | 5 | 2022 | 20218 | 0.130 |
Why?
|
Bioethics | 1 | 2018 | 118 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 878 | 0.130 |
Why?
|
Algorithms | 6 | 2014 | 14163 | 0.130 |
Why?
|
Aging | 3 | 2012 | 8744 | 0.130 |
Why?
|
Sweden | 1 | 2019 | 1382 | 0.130 |
Why?
|
Membrane Transport Proteins | 2 | 2017 | 1037 | 0.130 |
Why?
|
Antitubercular Agents | 3 | 2011 | 1397 | 0.130 |
Why?
|
West Nile virus | 1 | 2016 | 77 | 0.130 |
Why?
|
Neisseria meningitidis | 1 | 2016 | 111 | 0.130 |
Why?
|
RNA Virus Infections | 1 | 2015 | 19 | 0.130 |
Why?
|
Peer Review | 1 | 2018 | 218 | 0.130 |
Why?
|
Gene Flow | 1 | 2016 | 79 | 0.130 |
Why?
|
Catheter-Related Infections | 1 | 2019 | 275 | 0.130 |
Why?
|
Insurance, Liability | 1 | 2016 | 100 | 0.130 |
Why?
|
Statistics, Nonparametric | 2 | 2013 | 2863 | 0.130 |
Why?
|
Temperature | 4 | 2013 | 2234 | 0.120 |
Why?
|
Health Services Research | 2 | 2020 | 1815 | 0.120 |
Why?
|
Infant, Newborn, Diseases | 1 | 2020 | 587 | 0.120 |
Why?
|
Imipenem | 1 | 2014 | 38 | 0.120 |
Why?
|
Enterobacter | 1 | 2014 | 44 | 0.120 |
Why?
|
Codon | 1 | 2017 | 599 | 0.120 |
Why?
|
AIDS Serodiagnosis | 1 | 2016 | 220 | 0.120 |
Why?
|
Ceftazidime | 1 | 2014 | 57 | 0.120 |
Why?
|
Circumcision, Male | 1 | 2016 | 148 | 0.120 |
Why?
|
Nasopharyngeal Diseases | 2 | 2012 | 27 | 0.120 |
Why?
|
Human Experimentation | 1 | 2015 | 125 | 0.120 |
Why?
|
Moral Obligations | 1 | 2015 | 91 | 0.120 |
Why?
|
Capital Financing | 1 | 2014 | 58 | 0.120 |
Why?
|
Treatment Refusal | 1 | 1998 | 433 | 0.120 |
Why?
|
Expressed Sequence Tags | 1 | 2015 | 251 | 0.120 |
Why?
|
Malaria | 1 | 2004 | 1249 | 0.120 |
Why?
|
Regression Analysis | 3 | 2013 | 6339 | 0.120 |
Why?
|
Spain | 2 | 2020 | 484 | 0.120 |
Why?
|
Dengue Virus | 1 | 2016 | 204 | 0.110 |
Why?
|
Child Mortality | 2 | 2020 | 204 | 0.110 |
Why?
|
Condoms | 1 | 2016 | 337 | 0.110 |
Why?
|
Gene Order | 1 | 2014 | 166 | 0.110 |
Why?
|
Ethiopia | 3 | 2004 | 485 | 0.110 |
Why?
|
Cytomegalovirus Infections | 1 | 2020 | 836 | 0.110 |
Why?
|
Fungi | 1 | 1997 | 345 | 0.110 |
Why?
|
Genes, RAG-1 | 1 | 2013 | 68 | 0.110 |
Why?
|
Genome, Viral | 2 | 2014 | 674 | 0.110 |
Why?
|
Minority Groups | 1 | 2021 | 1217 | 0.110 |
Why?
|
Plasmids | 2 | 2014 | 2269 | 0.110 |
Why?
|
Myocarditis | 1 | 2021 | 802 | 0.110 |
Why?
|
Immunologic Memory | 1 | 2020 | 1377 | 0.110 |
Why?
|
Tuberculosis, Multidrug-Resistant | 3 | 2013 | 944 | 0.110 |
Why?
|
Mycoses | 1 | 1997 | 386 | 0.110 |
Why?
|
Treatment Outcome | 10 | 2022 | 65364 | 0.110 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2107 | 0.110 |
Why?
|
DNA, Bacterial | 5 | 2013 | 1478 | 0.110 |
Why?
|
Fever | 2 | 2011 | 1613 | 0.110 |
Why?
|
Virulence Factors | 1 | 2016 | 502 | 0.110 |
Why?
|
Retrospective Studies | 14 | 2024 | 81746 | 0.110 |
Why?
|
Heat-Shock Proteins | 1 | 2017 | 797 | 0.100 |
Why?
|
Vaccines, Subunit | 1 | 2013 | 159 | 0.100 |
Why?
|
Shiga-Toxigenic Escherichia coli | 1 | 2013 | 26 | 0.100 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 2004 | 766 | 0.100 |
Why?
|
Complement C3b | 1 | 2012 | 98 | 0.100 |
Why?
|
Gene Frequency | 3 | 2013 | 3623 | 0.100 |
Why?
|
Interleukin-17 | 3 | 2008 | 924 | 0.100 |
Why?
|
Intensive Care Units | 4 | 2020 | 3800 | 0.100 |
Why?
|
Laboratory Infection | 1 | 2012 | 7 | 0.100 |
Why?
|
Informed Consent | 1 | 2019 | 1010 | 0.100 |
Why?
|
Comorbidity | 3 | 2019 | 10590 | 0.100 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 804 | 0.100 |
Why?
|
Cholera Toxin | 2 | 2013 | 562 | 0.100 |
Why?
|
Pacific Ocean | 1 | 2012 | 16 | 0.100 |
Why?
|
Animal Migration | 1 | 2012 | 7 | 0.100 |
Why?
|
Brazil | 1 | 2016 | 1250 | 0.100 |
Why?
|
Zimbabwe | 1 | 2012 | 135 | 0.100 |
Why?
|
Models, Economic | 1 | 2016 | 719 | 0.100 |
Why?
|
Water Purification | 1 | 2012 | 61 | 0.100 |
Why?
|
Endocarditis | 1 | 2016 | 352 | 0.100 |
Why?
|
Enterococcus | 2 | 2004 | 159 | 0.100 |
Why?
|
Pseudomonas aeruginosa | 2 | 2014 | 1276 | 0.100 |
Why?
|
Administration, Oral | 1 | 2020 | 4030 | 0.100 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2014 | 149 | 0.100 |
Why?
|
Canada | 2 | 2009 | 2129 | 0.100 |
Why?
|
Longitudinal Studies | 5 | 2018 | 14783 | 0.100 |
Why?
|
Endocarditis, Bacterial | 1 | 2015 | 436 | 0.090 |
Why?
|
Anti-HIV Agents | 2 | 2019 | 4573 | 0.090 |
Why?
|
Germ Cells | 1 | 2015 | 644 | 0.090 |
Why?
|
Gram-Positive Bacterial Infections | 2 | 2004 | 342 | 0.090 |
Why?
|
Administration, Intranasal | 4 | 2007 | 485 | 0.090 |
Why?
|
Case-Control Studies | 6 | 2021 | 22287 | 0.090 |
Why?
|
Wales | 1 | 2011 | 87 | 0.090 |
Why?
|
Thailand | 1 | 2012 | 288 | 0.090 |
Why?
|
Rotavirus Infections | 1 | 2012 | 85 | 0.090 |
Why?
|
Feasibility Studies | 2 | 2021 | 5314 | 0.090 |
Why?
|
Technology, Pharmaceutical | 1 | 2011 | 84 | 0.090 |
Why?
|
Commerce | 1 | 2016 | 612 | 0.090 |
Why?
|
Residence Characteristics | 1 | 2021 | 2118 | 0.090 |
Why?
|
Complement C3 | 1 | 2012 | 434 | 0.090 |
Why?
|
Michigan | 1 | 2011 | 330 | 0.090 |
Why?
|
Viral Proteins | 2 | 2016 | 1802 | 0.090 |
Why?
|
Meningitis, Pneumococcal | 1 | 2010 | 43 | 0.090 |
Why?
|
Microsatellite Repeats | 1 | 2013 | 784 | 0.090 |
Why?
|
Measles Vaccine | 1 | 2010 | 79 | 0.090 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26375 | 0.090 |
Why?
|
Haiti | 1 | 2012 | 553 | 0.090 |
Why?
|
Leukocyte Reduction Procedures | 1 | 2009 | 13 | 0.090 |
Why?
|
RNA | 1 | 2020 | 2718 | 0.090 |
Why?
|
Antibiotic Prophylaxis | 1 | 2015 | 640 | 0.080 |
Why?
|
Base Sequence | 4 | 2014 | 12418 | 0.080 |
Why?
|
Odds Ratio | 3 | 2018 | 9666 | 0.080 |
Why?
|
Multigene Family | 1 | 2013 | 1081 | 0.080 |
Why?
|
International Classification of Diseases | 3 | 2022 | 936 | 0.080 |
Why?
|
Vapor Pressure | 1 | 2009 | 1 | 0.080 |
Why?
|
Denmark | 1 | 2012 | 776 | 0.080 |
Why?
|
Health Care Costs | 2 | 2018 | 3239 | 0.080 |
Why?
|
Licensure | 2 | 2020 | 127 | 0.080 |
Why?
|
Mortality | 3 | 2020 | 2910 | 0.080 |
Why?
|
Philadelphia | 1 | 2009 | 271 | 0.080 |
Why?
|
Prospective Studies | 8 | 2018 | 54924 | 0.080 |
Why?
|
Logistic Models | 5 | 2017 | 13289 | 0.080 |
Why?
|
Disease Notification | 1 | 2009 | 95 | 0.080 |
Why?
|
Models, Animal | 1 | 2015 | 2120 | 0.080 |
Why?
|
Isoniazid | 2 | 2011 | 288 | 0.080 |
Why?
|
Attitude of Health Personnel | 1 | 2003 | 3929 | 0.080 |
Why?
|
Primary Prevention | 1 | 2016 | 1188 | 0.080 |
Why?
|
Vibrio cholerae | 1 | 2015 | 793 | 0.080 |
Why?
|
Immunocompromised Host | 1 | 2014 | 863 | 0.080 |
Why?
|
Absenteeism | 1 | 2010 | 247 | 0.080 |
Why?
|
Proteome | 1 | 2018 | 1890 | 0.080 |
Why?
|
Family Health | 2 | 2010 | 1255 | 0.080 |
Why?
|
Cells, Cultured | 3 | 2013 | 19017 | 0.080 |
Why?
|
Inpatients | 1 | 2020 | 2570 | 0.080 |
Why?
|
Food Microbiology | 1 | 2008 | 74 | 0.080 |
Why?
|
Latent Tuberculosis | 1 | 2011 | 224 | 0.080 |
Why?
|
Colonoscopy | 1 | 2016 | 1409 | 0.080 |
Why?
|
Helicobacter pylori | 1 | 2011 | 380 | 0.070 |
Why?
|
Occupational Health | 1 | 2014 | 812 | 0.070 |
Why?
|
Rural Population | 1 | 2019 | 2325 | 0.070 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 1995 | 1354 | 0.070 |
Why?
|
Cohort Studies | 6 | 2022 | 41749 | 0.070 |
Why?
|
Helicobacter Infections | 1 | 2011 | 390 | 0.070 |
Why?
|
Decision Making | 3 | 2019 | 3952 | 0.070 |
Why?
|
Rain | 2 | 2004 | 60 | 0.070 |
Why?
|
HIV | 1 | 1995 | 1597 | 0.070 |
Why?
|
Public Policy | 1 | 2012 | 552 | 0.070 |
Why?
|
Patient Compliance | 1 | 2018 | 2697 | 0.070 |
Why?
|
Protein Binding | 2 | 2018 | 9343 | 0.070 |
Why?
|
Multivariate Analysis | 6 | 2012 | 12075 | 0.070 |
Why?
|
Parents | 1 | 2022 | 3595 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 2 | 2007 | 18062 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 3813 | 0.070 |
Why?
|
Insurance, Health | 1 | 2020 | 2517 | 0.070 |
Why?
|
Health Personnel | 1 | 2021 | 3385 | 0.070 |
Why?
|
Asymptomatic Diseases | 2 | 2021 | 590 | 0.070 |
Why?
|
Health Promotion | 1 | 2019 | 2210 | 0.070 |
Why?
|
Double-Blind Method | 2 | 2018 | 12464 | 0.070 |
Why?
|
Cohort Effect | 1 | 2007 | 39 | 0.070 |
Why?
|
Resource Allocation | 1 | 2009 | 354 | 0.070 |
Why?
|
Public Opinion | 1 | 2011 | 485 | 0.070 |
Why?
|
Fructose | 1 | 2009 | 284 | 0.070 |
Why?
|
Geography | 2 | 2014 | 652 | 0.070 |
Why?
|
Sensitivity and Specificity | 3 | 2009 | 14718 | 0.070 |
Why?
|
Respiratory Tract Diseases | 1 | 2012 | 744 | 0.070 |
Why?
|
Planning Techniques | 1 | 2007 | 81 | 0.070 |
Why?
|
Antibodies | 1 | 2015 | 2421 | 0.070 |
Why?
|
Socioeconomic Factors | 2 | 2018 | 7851 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2533 | 0.070 |
Why?
|
Environmental Pollutants | 1 | 2016 | 1296 | 0.070 |
Why?
|
Poisson Distribution | 2 | 2004 | 506 | 0.070 |
Why?
|
Occupational Diseases | 1 | 2014 | 1457 | 0.070 |
Why?
|
Streptolysins | 2 | 2004 | 61 | 0.070 |
Why?
|
Chromosome Mapping | 1 | 2014 | 4618 | 0.070 |
Why?
|
Mucous Membrane | 1 | 2009 | 659 | 0.070 |
Why?
|
DNA | 1 | 2020 | 7213 | 0.070 |
Why?
|
History, 21st Century | 1 | 2012 | 1572 | 0.060 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2007 | 412 | 0.060 |
Why?
|
Catalase | 1 | 2006 | 215 | 0.060 |
Why?
|
Universities | 1 | 2011 | 1005 | 0.060 |
Why?
|
Intestines | 1 | 2015 | 1909 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2018 | 5536 | 0.060 |
Why?
|
Phenotype | 4 | 2014 | 16723 | 0.060 |
Why?
|
Molecular Sequence Data | 4 | 2014 | 17617 | 0.060 |
Why?
|
Ethics Committees | 1 | 2005 | 51 | 0.060 |
Why?
|
Evidence-Based Practice | 1 | 2009 | 500 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2018 | 16041 | 0.060 |
Why?
|
Ethicists | 1 | 2005 | 39 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3231 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2017 | 39345 | 0.060 |
Why?
|
Developing Countries | 1 | 2017 | 2913 | 0.060 |
Why?
|
Ecosystem | 1 | 2008 | 494 | 0.060 |
Why?
|
Pneumonia | 2 | 2013 | 2163 | 0.060 |
Why?
|
Morbidity | 1 | 2009 | 1754 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5366 | 0.060 |
Why?
|
Vietnam | 1 | 2004 | 415 | 0.050 |
Why?
|
Patient Transfer | 1 | 2010 | 790 | 0.050 |
Why?
|
Area Under Curve | 2 | 2020 | 1642 | 0.050 |
Why?
|
Cell Wall | 1 | 2006 | 421 | 0.050 |
Why?
|
Bacterial Physiological Phenomena | 2 | 2000 | 120 | 0.050 |
Why?
|
Patient Isolation | 1 | 2003 | 101 | 0.050 |
Why?
|
Animals, Domestic | 1 | 2002 | 56 | 0.050 |
Why?
|
Campylobacter | 1 | 2002 | 58 | 0.050 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2006 | 664 | 0.050 |
Why?
|
Linkage Disequilibrium | 2 | 2018 | 1997 | 0.050 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2006 | 1353 | 0.050 |
Why?
|
Age of Onset | 1 | 2009 | 3347 | 0.050 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2004 | 238 | 0.050 |
Why?
|
Treatment Failure | 2 | 2021 | 2660 | 0.050 |
Why?
|
Endemic Diseases | 1 | 2003 | 191 | 0.050 |
Why?
|
Sex Factors | 2 | 2013 | 10627 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2021 | 15660 | 0.050 |
Why?
|
Malawi | 1 | 2023 | 312 | 0.050 |
Why?
|
Kidney Diseases | 1 | 2012 | 2100 | 0.050 |
Why?
|
Anti-Retroviral Agents | 2 | 2012 | 1789 | 0.050 |
Why?
|
Lactams | 1 | 2022 | 159 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2006 | 1743 | 0.050 |
Why?
|
Herpes Genitalis | 1 | 2002 | 149 | 0.050 |
Why?
|
Gene Transfer, Horizontal | 1 | 2002 | 148 | 0.050 |
Why?
|
Carnobacteriaceae | 1 | 2020 | 10 | 0.050 |
Why?
|
Medicare | 2 | 2018 | 6809 | 0.050 |
Why?
|
Herpesvirus 2, Human | 1 | 2002 | 191 | 0.050 |
Why?
|
Amoxicillin | 2 | 2018 | 181 | 0.050 |
Why?
|
Cefotaxime | 1 | 2000 | 36 | 0.050 |
Why?
|
Vancomycin | 1 | 2004 | 504 | 0.050 |
Why?
|
Leucine | 1 | 2022 | 547 | 0.040 |
Why?
|
Proline | 1 | 2022 | 455 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6517 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2004 | 991 | 0.040 |
Why?
|
Voluntary Programs | 1 | 2020 | 48 | 0.040 |
Why?
|
Gene Deletion | 1 | 2008 | 2673 | 0.040 |
Why?
|
Streptococcus | 1 | 2020 | 198 | 0.040 |
Why?
|
Ritonavir | 1 | 2022 | 331 | 0.040 |
Why?
|
Disease Models, Animal | 5 | 2012 | 18344 | 0.040 |
Why?
|
Monte Carlo Method | 2 | 2020 | 1259 | 0.040 |
Why?
|
Genes, Recessive | 1 | 2003 | 625 | 0.040 |
Why?
|
Serologic Tests | 1 | 2002 | 382 | 0.040 |
Why?
|
Genes, Dominant | 1 | 2003 | 855 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2013 | 14486 | 0.040 |
Why?
|
Emigration and Immigration | 1 | 2003 | 406 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2017 | 7876 | 0.040 |
Why?
|
Aircraft | 1 | 2021 | 135 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 621 | 0.040 |
Why?
|
Luminescent Measurements | 1 | 2001 | 342 | 0.040 |
Why?
|
Amino Acid Sequence | 2 | 2014 | 13420 | 0.040 |
Why?
|
United States Department of Veterans Affairs | 1 | 2024 | 937 | 0.040 |
Why?
|
Acute Disease | 2 | 2021 | 7241 | 0.040 |
Why?
|
Bangladesh | 1 | 2021 | 742 | 0.040 |
Why?
|
Ontario | 1 | 2020 | 403 | 0.040 |
Why?
|
Family | 1 | 2010 | 3210 | 0.040 |
Why?
|
Clavulanic Acid | 1 | 2018 | 19 | 0.040 |
Why?
|
Aluminum Hydroxide | 1 | 2018 | 55 | 0.040 |
Why?
|
Herpes Zoster | 1 | 2021 | 252 | 0.040 |
Why?
|
Puerto Rico | 1 | 2020 | 380 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2006 | 1801 | 0.040 |
Why?
|
Policy | 1 | 2022 | 513 | 0.040 |
Why?
|
Africa | 1 | 2021 | 725 | 0.040 |
Why?
|
Homozygote | 1 | 2003 | 1778 | 0.040 |
Why?
|
Privacy | 1 | 2020 | 233 | 0.040 |
Why?
|
Crossing Over, Genetic | 1 | 1997 | 92 | 0.040 |
Why?
|
Social Isolation | 1 | 2020 | 366 | 0.040 |
Why?
|
Sierra Leone | 1 | 2017 | 171 | 0.040 |
Why?
|
Glucose | 1 | 2009 | 4351 | 0.040 |
Why?
|
DNA Transposable Elements | 1 | 2001 | 764 | 0.040 |
Why?
|
Insurance | 1 | 2018 | 115 | 0.040 |
Why?
|
Adjuvants, Immunologic | 2 | 2018 | 998 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2018 | 399 | 0.030 |
Why?
|
Nitriles | 1 | 2022 | 980 | 0.030 |
Why?
|
Critical Care | 1 | 2009 | 2715 | 0.030 |
Why?
|
Dengue | 1 | 2020 | 258 | 0.030 |
Why?
|
Metagenome | 1 | 2020 | 465 | 0.030 |
Why?
|
Medicare Part C | 1 | 2022 | 332 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2020 | 1049 | 0.030 |
Why?
|
DNA, Fungal | 1 | 1997 | 275 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2020 | 751 | 0.030 |
Why?
|
Drug Combinations | 1 | 2022 | 2089 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2020 | 620 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2015 | 6973 | 0.030 |
Why?
|
Drug Therapy, Combination | 3 | 2009 | 6314 | 0.030 |
Why?
|
Length of Stay | 1 | 2009 | 6495 | 0.030 |
Why?
|
Operon | 2 | 2010 | 371 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2008 | 9556 | 0.030 |
Why?
|
Arabs | 1 | 2017 | 190 | 0.030 |
Why?
|
Survival | 1 | 2015 | 160 | 0.030 |
Why?
|
Pregnancy | 3 | 2021 | 30260 | 0.030 |
Why?
|
Rats | 3 | 2007 | 23751 | 0.030 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2015 | 39 | 0.030 |
Why?
|
HTLV-I Infections | 1 | 1995 | 104 | 0.030 |
Why?
|
Minnesota | 1 | 2015 | 339 | 0.030 |
Why?
|
Appendicitis | 1 | 2021 | 691 | 0.030 |
Why?
|
Dogs | 1 | 2019 | 3844 | 0.030 |
Why?
|
Public Health Administration | 1 | 1997 | 242 | 0.030 |
Why?
|
Medical Record Linkage | 1 | 2015 | 286 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 4576 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 5887 | 0.030 |
Why?
|
Propensity Score | 1 | 2022 | 1970 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2016 | 15831 | 0.030 |
Why?
|
Prognosis | 3 | 2021 | 29979 | 0.030 |
Why?
|
Research Personnel | 1 | 2018 | 589 | 0.030 |
Why?
|
Drosophila Proteins | 1 | 2003 | 1712 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2003 | 2819 | 0.030 |
Why?
|
Entropy | 1 | 2014 | 211 | 0.030 |
Why?
|
Attitude | 1 | 2018 | 771 | 0.030 |
Why?
|
Genetic Speciation | 1 | 2013 | 38 | 0.030 |
Why?
|
Research Subjects | 1 | 2015 | 249 | 0.030 |
Why?
|
Genetic Markers | 1 | 2019 | 2602 | 0.030 |
Why?
|
Disease Progression | 2 | 2017 | 13665 | 0.030 |
Why?
|
Environmental Exposure | 1 | 2008 | 4543 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2020 | 1758 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11101 | 0.030 |
Why?
|
Interspersed Repetitive Sequences | 1 | 2013 | 52 | 0.030 |
Why?
|
Antibiotics, Antitubercular | 1 | 2013 | 100 | 0.030 |
Why?
|
Animals, Newborn | 2 | 2009 | 2678 | 0.030 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2013 | 106 | 0.030 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 3251 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2013 | 161 | 0.030 |
Why?
|
Ventilation | 1 | 2013 | 129 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2003 | 3710 | 0.020 |
Why?
|
New Mexico | 1 | 2011 | 81 | 0.020 |
Why?
|
Arizona | 1 | 2011 | 108 | 0.020 |
Why?
|
Clinical Protocols | 1 | 1997 | 1443 | 0.020 |
Why?
|
Policy Making | 1 | 2015 | 546 | 0.020 |
Why?
|
Calibration | 1 | 2014 | 819 | 0.020 |
Why?
|
Methicillin | 1 | 2011 | 62 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2002 | 2972 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2018 | 1311 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2012 | 8761 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2015 | 2178 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2276 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 3210 | 0.020 |
Why?
|
Methicillin Resistance | 1 | 2011 | 198 | 0.020 |
Why?
|
SEER Program | 1 | 2015 | 1444 | 0.020 |
Why?
|
Demography | 1 | 1995 | 1641 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1903 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2019 | 1238 | 0.020 |
Why?
|
Mothers | 1 | 2020 | 2209 | 0.020 |
Why?
|
United Nations | 1 | 2010 | 151 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2014 | 2748 | 0.020 |
Why?
|
Immunization Schedule | 1 | 2010 | 228 | 0.020 |
Why?
|
Medical Audit | 1 | 2010 | 454 | 0.020 |
Why?
|
Netherlands | 1 | 2014 | 2277 | 0.020 |
Why?
|
Neuraminidase | 1 | 2009 | 195 | 0.020 |
Why?
|
International Cooperation | 1 | 2015 | 1434 | 0.020 |
Why?
|
Macaca fascicularis | 1 | 2011 | 912 | 0.020 |
Why?
|
Patient Selection | 1 | 2021 | 4258 | 0.020 |
Why?
|
Rabbits | 1 | 2015 | 4771 | 0.020 |
Why?
|
Carbon Dioxide | 1 | 2013 | 1148 | 0.020 |
Why?
|
HIV-1 | 1 | 2006 | 6960 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 21206 | 0.020 |
Why?
|
Recurrence | 1 | 2000 | 8507 | 0.020 |
Why?
|
Nasal Cavity | 1 | 2009 | 310 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2022 | 12797 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9384 | 0.020 |
Why?
|
Saccharomyces cerevisiae | 1 | 1997 | 2680 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1995 | 2204 | 0.020 |
Why?
|
Environmental Monitoring | 1 | 2013 | 1469 | 0.020 |
Why?
|
Idaho | 1 | 2005 | 17 | 0.020 |
Why?
|
ROC Curve | 1 | 2014 | 3628 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 2923 | 0.020 |
Why?
|
Diarrhea | 1 | 2013 | 1320 | 0.020 |
Why?
|
Adoptive Transfer | 1 | 2008 | 825 | 0.020 |
Why?
|
Utah | 1 | 2005 | 130 | 0.020 |
Why?
|
Software | 1 | 2020 | 4478 | 0.020 |
Why?
|
Australia | 1 | 2009 | 1265 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2007 | 687 | 0.020 |
Why?
|
Lymphocyte Depletion | 1 | 2007 | 605 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3435 | 0.020 |
Why?
|
Drug Industry | 1 | 2011 | 791 | 0.010 |
Why?
|
Culicidae | 1 | 2004 | 111 | 0.010 |
Why?
|
Nutrition Surveys | 1 | 2011 | 1738 | 0.010 |
Why?
|
Immunoglobulins | 1 | 2007 | 854 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15442 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 2 | 2007 | 8120 | 0.010 |
Why?
|
Africa South of the Sahara | 1 | 2006 | 752 | 0.010 |
Why?
|
Protein Subunits | 1 | 2006 | 943 | 0.010 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2003 | 294 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2022 | 7939 | 0.010 |
Why?
|
Self Report | 1 | 2014 | 3773 | 0.010 |
Why?
|
Lung | 1 | 2001 | 10094 | 0.010 |
Why?
|
Macrophages, Peritoneal | 1 | 2003 | 244 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 2003 | 915 | 0.010 |
Why?
|
Risk-Taking | 1 | 2007 | 1023 | 0.010 |
Why?
|
Trachea | 1 | 2007 | 1095 | 0.010 |
Why?
|
Spleen | 1 | 2007 | 2295 | 0.010 |
Why?
|
Toll-Like Receptor 2 | 1 | 2003 | 348 | 0.010 |
Why?
|
Porins | 1 | 2000 | 78 | 0.010 |
Why?
|
Mice, Nude | 1 | 2006 | 3620 | 0.010 |
Why?
|
Toll-Like Receptors | 1 | 2003 | 582 | 0.010 |
Why?
|
Lipoproteins | 1 | 2004 | 879 | 0.010 |
Why?
|
Virus Physiological Phenomena | 1 | 1999 | 15 | 0.010 |
Why?
|
Chromosomes, Bacterial | 1 | 2000 | 281 | 0.010 |
Why?
|
Toll-Like Receptor 4 | 1 | 2003 | 588 | 0.010 |
Why?
|
Cricetinae | 1 | 2003 | 2423 | 0.010 |
Why?
|
Immunization, Passive | 1 | 2001 | 619 | 0.010 |
Why?
|
DNA Primers | 1 | 2003 | 2827 | 0.010 |
Why?
|
Patient Discharge | 1 | 2010 | 3476 | 0.010 |
Why?
|
R Factors | 1 | 1997 | 35 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2002 | 1666 | 0.010 |
Why?
|
Cell Survival | 1 | 2006 | 5772 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1997 | 1625 | 0.010 |
Why?
|
Drug Therapy | 1 | 1997 | 504 | 0.010 |
Why?
|
Macrophages | 1 | 2009 | 5799 | 0.010 |
Why?
|
Cytokines | 1 | 2009 | 7450 | 0.010 |
Why?
|
Cell Division | 1 | 2000 | 4473 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2003 | 5902 | 0.010 |
Why?
|
Apoptosis | 1 | 2007 | 9521 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2004 | 4937 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2001 | 5798 | 0.010 |
Why?
|
Cell Line | 1 | 2003 | 15597 | 0.000 |
Why?
|
DNA Repair | 1 | 1997 | 2050 | 0.000 |
Why?
|